UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 578,947 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are approximately $110.0 million. All of the shares in the offering are to be sold by Merus.
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
